Evaluation of cisatracurium a new blocking agent, tracheal intubation

Canadian Journal of Anaesthesia

Volumn 43, Issue 9, 1996, Pages 925-931

  Bluestein, Linda S ^b   Stinson Jr , Lawrence W ^b   Lennon Do, Robert L ^a   Quessy, Stephen N ^b   Wilson, Rebecca M ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

Anesthetics, intravenous: propofol; Intubation: tracheal; Neuromuscular relaxants: atracurium, cisatracurium, 51W89

Indexed keywords

ATRACURIUM; CISATRACURIUM; FENTANYL; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; PROPOFOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOTRACHEAL INTUBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029786780     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03011806     Document Type: Article

References (16)

1. Tsui D, Graham GG, Torda TA. The pharmacokinetics of atracurium isomers in vitro and in humans. Anesthesiology 1987; 67: 722-8.
2. Wastila WB, Maehr RB. The pharmacological profile of 51W89, the R, Cis- R', Cis isomer of atracurium in cats. Anesthesiology 1993; 79: A946.
3. Belmont MR, Lien CA, Quessy S, et al. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82: 1139-45.
4. Lepage JY, Malinovsky JM, Malinge M, Cozian A, Pinaud M. 51W89: Dose-response, neuromuscular blocking profile and cardiovascular effects. Anesthesiology 1993; 79(Suppl 3A): A945.
5. Lien CA, Belmont MR, Abalos A, et al. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82: 1131-8.
6. Lennon RL, Oison RA, Gronert GA. Atracurium or vecuronium for rapid sequence endotracheal intubation. Anesthesiology 1986; 64: 510-3.
7. Siler JN, Mager JG Jr, Wyche MQ Jr. Atracurium: hypotension, tachycardia and bronchospasm. Anesthesiology 1985; 62: 645-6.
8. Donati F, Meistelman C, Plaud B. Vecuronium neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis. Anesthesiology 1991; 74: 833-7.
9. Pansard J-L, Chauvin M, Lebrault C, Gauneau P, Duvaldestin P. Effect of an intubating dose of succinylcholine and atracurium on the diaphragm and the adductor pollicis muscle in humans. Anesthesiology 1987; 67: 326-30.
10. Miller RD, Rupp SM, Fisher DM, Cronnelly R, Fahey MR, Sohn YJ. Clinical pharmacology of vecuronium and atracurium. Anesthesiology 1984; 61: 444-53.
11. Scott RPF, Savarese JJ, Basta SJ, et al. Clinical pharmacology of atracurium given in high dose. Br J Anaesth 1986; 58: 834-8.
12. Tullock WC, Diana P, Cook DR, et al. Neuromuscular and cardiovascular effects of high-dose vecuronium. Anesth Analg 1990; 70: 86-90.
13. Hosking MP, Lennon RL, Gronert GA. Combined and receptor blockade attenuates the cardiovascular effects of high-dose atracurium for rapid sequence endotracheal intubation. Anesth Analg 1988; 67: 1089-92.
14. Ginsberg B, Glass PS, Quill T, Shafron D, Ossey KD. Onset and duration of neuromuscular blockade following high-dose vecuronium administration. Anesthesiology 1989: 71: 201-5.
15. Casson WR, Jones RM. Vecuronium induced neuromuscular blockade. The effect of increasing dose on speed of onset. Anaesthesia 1986; 41: 354-7.
16. Kaufman JA, Dubois MY, Chen JC, Lea DE. Pharmacodynamic effects of vecuronium: a dose response study. J Clin Anesth 1989; 1: 434-9.